Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 1-Year Low - What's Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares hit a new 52-week low during trading on Wednesday . The company traded as low as $16.88 and last traded at $17.71, with a volume of 6181226 shares. The stock had previously closed at $17.10.

Analysts Set New Price Targets

A number of brokerages have commented on SRPT. Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. TD Cowen lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective for the company. in a report on Wednesday, June 18th. Needham & Company LLC decreased their price objective on Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating for the company in a report on Monday, June 16th. Bank of America reissued a "neutral" rating and set a $28.00 price objective (down from $76.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. Finally, Oppenheimer decreased their price objective on Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a report on Friday, June 20th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $60.88.

Sarepta Therapeutics Trading Up 0.1%

The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $35.34 and a 200 day moving average of $75.11. The firm has a market cap of $1.79 billion, a PE ratio of -6.77 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the previous year, the company posted $0.73 EPS. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the company. Capital International Investors boosted its holdings in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth $126,315,000. Assenagon Asset Management S.A. boosted its holdings in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after acquiring an additional 580,123 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after acquiring an additional 577,848 shares during the period. Finally, EcoR1 Capital LLC boosted its holdings in shares of Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after acquiring an additional 522,386 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.